Goodwin advised Germitec, a leading MedTech company specializing in UV-C High-Level Disinfection solutions, on its €29 million Series B financing round.
The round was led by Eurazeo through its Nov Santé Actions Non Cotées fund, a platform dedicated to the development of healthcare sectors in Europe, and included existing investors Kurma Partners, Financière Arbevel and Turenne Capital.
Based in Bordeaux, Germitec has established itself as a leader in ultrasound probe disinfection. Operating in over 40 countries, the company is internationally recognized and is now expanding into new markets, including the United States, where it recently obtained FDA De Novo certification for its flagship product, Chronos.
The Goodwin team included Anne-Charlotte Rivière, Sonia Sassi and Inès Louguar on corporate aspects, and Marie Fillon on IP aspects. The firm has been advising Germitec since 2022, supporting it through multiple financing rounds.